Últimas noticias sobre Semler Scientific (NASDAQ:SMLR) Bolsa

Semler Scientific

Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test. also invest in bitcoin and have adopted bitcoin as its treasury reserve asset. Company's healthcare technology solutions business is predominant operational focus, providing cash flows and enabling it to pursue bitcoin.

A,Close-up,Image,Of,Cryptocurrency,Bitcoin,Meets,Classic,Banknotes,,Symbolizing

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

SMLR

Bitcoin (CRYPTO: BTC) bajó un 1,6 % este lunes hasta los 93.808 dólares, al tiempo que los inversores evaluaban el impulso de los flujos hacia ETFs frente a vientos macroeconómicos adversos y niveles técnicos de resistencia persistente.

Bitcoin cae 1,6 % mientras flujos ETF institucionales contrastan con la resistencia técnica

Blackrock,And,Bitcoin,Logo,On,Dark,Background,With,Shiny,Details.

News

MARA

MSTR

MTPLF

Bitcoin (CRYPTO: BTC) es cada vez más popular entre los compradores corporativos, con datos on-chain que sugieren la acumulación 

Bitcoin en el radar de empresas: compras millonarias y volatilidad

Semler Scientific Inc (NASDAQ:SMLR), una empresa de tecnología médica, ha anunciado un cambio significativo en el espacio de las criptomonedas con su última oferta de pagarés convertibles y los planes p

Semler Scientific adopta Bitcoin: Oferta de pagarés convertibles y planes de tesorería cripto

Semler Scientific Inc

Semler Scientific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares are seeing increased attention to start the week after the company announced a new board appointment that&#8217;s causing a spike in chatter on <a href="https://www.benzinga.com/topic/social-media">various social platforms</a>.
What To Know: Semler Scientific, a technology company that has adopted a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) treasury strategy, on Monday announced that it <a href="https://www.benzinga.com/pressreleases/25/05/n45490896/semler-scientific-appoints-natalie-brunell-to-its-board-of-directors">appointed</a> crypto journalist and podcast host&nbsp;Natalie Brunell&nbsp;to its board of directors.
Brunell is an influential crypto educator and hosts a popular Bitcoin podcast called &#8220;Coin Stories.&#8221; The company on Monday said that its latest board addition reflects its continued commitment to its Bitcoin treasury strategy. 
&#8220;Natalie is a highly respected journalist and educator – and a leading advocate for&nbsp;Bitcoin, with a deep understanding of its role as a transformative asset. As the 4th&nbsp;largest U.S. public company on the&nbsp;Bitcoin&nbsp;Standard in terms of&nbsp;Bitcoin&nbsp;holdings, we believe we are a strategic asset. Her insights will be instrumental as we pursue our&nbsp;Bitcoin&nbsp;treasury strategy and aim to deliver long-term value to our stockholders,&#8221; said Eric Semler, chairman of Semler Scientific.
Semler is seeing increased attention on multiple social platforms, especially on X, where the company is being talked about in comparison to Strategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>). 
Strategy&#8217;s Michael Saylor <a href="https://x.com/saylor/status/1924440559634076050">congratulated</a> the Semler team on X in response to a post from the company&#8217;s chairman. He also <a href="https://x.com/saylor/status/1924444076192981375">responded</a> to a post from Brunell announcing the new appointment. 
In&nbsp;May 2024, Semler Scientific became the second publicly traded company in the U.S. to adopt a&nbsp;Bitcoin&nbsp;treasury strategy, which involves using proceeds from equity and debt financings, as well as cash flows from operations, to strategically accumulate&nbsp;Bitcoin.
Semler reported first-quarter financial results last week, reporting Bitcoin treasury highlights similar to Strategy. The company said it achieved a &#8220;BTC Yield&#8221; of 21.9% in the first quarter and reported a &#8220;BTC Gain&#8221; of 7.1 in the first quarter and 510.3 year-to-date. The company said it held a total of 3,192 Bitcoin as of March 31. 
SMLR Price Action: <a href="http://benzinga.com/quote/SMLR">Semler Scientific shares</a> were up 7.84% at $44.08 at the time of publication Monday, according to Benzinga Pro. The company&#8217;s stock is down approximately 18% year-to-date, but has risen 88% over a one-year period on the back of its Bitcoin treasury strategy announcement.
Photo: Yalcin Sonat/Shutterstock.

Movers

Bitcoin-Linked Semler Scientific Stock Is Trending On Monday: What's Going On?

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday.
Shares of Evolv Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) rose sharply during Friday's session after the <a href="https://www.benzinga.com/quote/EVLV">company announced preliminary first-quarter financial results.</a>
The company said it expects revenue growth of 40%+ in the first quarter.
Evolv Technologies shares jumped 21% to $5.08 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) jumped 33.7% to $12.34 after the company reported better-than-expected quarterly EPS results.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) gained 30.2% to $1.64. NWTN announced the appointment of Mr. Benjamin Zhai as Executive Director of the Board and Global Chief Executive Officer.</li>
<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) rose 29% to $22.70 after a court decision ruled in favor of the company regarding patent infringement claims over Nuplazid.</li>
<li>Advantage Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) gained 24.7% to $1.3596.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 18.5% to $77.95 after Nvidia disclosed it added a stake in the company via a 13F filing equating to approximately 24.18 million shares. Additionally, JP Morgan and Needham raised their respective price targets on the stock.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) gained 18.5% to $6.64.</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) rose 14.4% to $36.36.</li>
<li>Archer Aviation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>) surged 10.3% to $13.45.</li>
<li>Vipshop Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) rose 7.5% to $15.59. Vipshop will announce first quarter 2025 financial results on May 20.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 7% to $430.00.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rose 6.8% to $261.17 after the company announced a partnership with Webull Pay to power crypto experiences. Additionally, Benchmark raised its price target on the stock from $252 to $301.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 5% to $51.35.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45462276/applied-materials-flowers-foods-and-3-stocks-to-watch-heading-into-friday">Applied Materials, Flowers Foods And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

ACAD

ACHR

APLD

COIN

CRWV

EVLV

HALO

NWTN

QUBT

VIPS

Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday

Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) reported quarterly losses of $(6.74) per share. This is a 964.1 percent decrease over earnings of $0.78 per share from the same period last year. The company reported $8.84 million in sales this quarter. This is a 44.44 percent decrease over sales of $15.90 million the same period last year.

Earnings

Semler Scientific Q1 EPS $(6.74) Down From $0.78 YoY, Sales $8.84M Down From $15.90M YoY

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

On May 6, it was revealed in an SEC filing that William Chang, Director at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) executed a significant exercise of company stock options.
What Happened: The latest Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465925044695//Archives/edgar/data/1554859/000110465925044695/0001104659-25-044695-index.htm">U.S. Securities and Exchange Commission</a> uncovered Chang, Director at Semler Scientific, exercising stock options for 0 shares of SMLR. The total transaction was valued at $0.
The latest update on Tuesday morning shows Semler Scientific shares down by 0.68%, trading at $33.35. At this price, Chang's 0 shares are worth $0.
<h3>Discovering Semler Scientific: A Closer Look</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test. also invest in bitcoin and have adopted bitcoin as its treasury reserve asset. Company's healthcare technology solutions business is predominant operational focus, providing cash flows and enabling it to pursue bitcoin.
<h3>Understanding the Numbers: Semler Scientific's Finances</h3>
Revenue Growth: Semler Scientific's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -17.56%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 91.12%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 3.64.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 6.55 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 4.76, Semler Scientific's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Semler Scientific's EV/EBITDA ratio, surpassing industry averages at 15.59, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Insider Decision Unfolding At Semler Scientific: William Chang Exercises Options, Resulting In $0

In a new SEC filing on May 6, it was revealed that MESSINA, Director at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), executed a significant exercise of company stock options.
What Happened: The latest Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465925044700//Archives/edgar/data/1554859/000110465925044700/0001104659-25-044700-index.htm">U.S. Securities and Exchange Commission</a> uncovered MESSINA, Director at Semler Scientific, exercising stock options for 0 shares of SMLR. The total transaction was valued at $0.
Semler Scientific shares are trading, exhibiting down of 0.68% and priced at $33.35 during Tuesday's morning. This values MESSINA's 0 shares at $0.
<h3>Get to Know Semler Scientific Better</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test. also invest in bitcoin and have adopted bitcoin as its treasury reserve asset. Company's healthcare technology solutions business is predominant operational focus, providing cash flows and enabling it to pursue bitcoin.
<h3>Semler Scientific: Delving into Financials</h3>
Revenue Challenges: Semler Scientific's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -17.56%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: With a high gross margin of 91.12%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 3.64.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.0, Semler Scientific adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 6.55 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 4.76 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 15.59 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision Making Waves At Semler Scientific: DANIEL MESSINA Exercises Options, Realizing $0

Disclosed in a recent SEC filing on May 6, Murphy-Chutorian, Chief Executive Officer at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465925044702//Archives/edgar/data/1554859/000110465925044702/0001104659-25-044702-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Murphy-Chutorian, Chief Executive Officer at Semler Scientific, a company in the Health Care sector, just exercised stock options worth 0 shares of SMLR stock with an exercise price of $0.0.
Semler Scientific shares are trading, exhibiting down of 0.68% and priced at $33.35 during Tuesday's morning. This values Murphy-Chutorian's 0 shares at $0.
<h3>Delving into Semler Scientific's Background</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test. also invest in bitcoin and have adopted bitcoin as its treasury reserve asset. Company's healthcare technology solutions business is predominant operational focus, providing cash flows and enabling it to pursue bitcoin.
<h3>Breaking Down Semler Scientific's Financial Performance</h3>
Revenue Challenges: Semler Scientific's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -17.56%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 91.12%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 3.64.
</li>
</ul>
Debt Management: Semler Scientific's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 6.55 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 4.76 is above industry norms, reflecting an elevated valuation for Semler Scientific's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 15.59, Semler Scientific demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision Unfolding At Semler Scientific: Douglas Murphy-Chutorian Exercises Options, Resulting In $0

Highlighted on May 6, it was unveiled in an SEC filing that SEMLER, Board Member at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), executed a significant transaction involving the exercise of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465925044703//Archives/edgar/data/1554859/000110465925044703/0001104659-25-044703-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that SEMLER, Board Member at Semler Scientific in the Health Care sector, exercised stock options for 0 shares of SMLR stock. The exercise price of the options was $0.0 per share.
During Tuesday's morning session, Semler Scientific shares down by 0.68%, currently priced at $33.35. Considering the current price, SEMLER's 0 shares have a total value of $0.
<h3>Unveiling the Story Behind Semler Scientific</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test. also invest in bitcoin and have adopted bitcoin as its treasury reserve asset. Company's healthcare technology solutions business is predominant operational focus, providing cash flows and enabling it to pursue bitcoin.
<h3>Semler Scientific: Financial Performance Dissected</h3>
Decline in Revenue: Over the 3 months period, Semler Scientific faced challenges, resulting in a decline of approximately -17.56% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 91.12%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 3.64, Semler Scientific showcases strong earnings per share.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: Semler Scientific's P/E ratio of 6.55 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 4.76, Semler Scientific's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 15.59, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes Worth Your Attention</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Update: ERIC SEMLER Engages In Options Exercise At Semler Scientific Realizing $0

A large exercise of company stock options by Renae Cormier, Chief Financial Officer at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) was disclosed in a new SEC filing on May 6, as part of an insider exercise.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465925044704//Archives/edgar/data/1554859/000110465925044704/0001104659-25-044704-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Cormier, Chief Financial Officer at Semler Scientific, a company in the Health Care sector, just exercised stock options worth 0 shares of SMLR stock with an exercise price of $0.0.
The Tuesday morning market activity shows Semler Scientific shares down by 0.68%, trading at $33.35. This implies a total value of $0 for Cormier's 0 shares.
<h3>Discovering Semler Scientific: A Closer Look</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test. also invest in bitcoin and have adopted bitcoin as its treasury reserve asset. Company's healthcare technology solutions business is predominant operational focus, providing cash flows and enabling it to pursue bitcoin.
<h3>Financial Insights: Semler Scientific</h3>
Negative Revenue Trend: Examining Semler Scientific's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -17.56% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a high gross margin of 91.12%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 3.64.
</li>
</ul>
Debt Management: Semler Scientific's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 6.55 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 4.76 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Semler Scientific's EV/EBITDA ratio of 15.59 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision Making Waves At Semler Scientific: Renae Cormier Exercises Options, Realizing $0

Semler Scientific Acquired 165 Bitcoins Between Apr. 25 And Apr. 29

Bill Miller IV&#8216;s investment firm has seen significant losses in its fourth-quarter portfolio additions as market uncertainties persist.
What Happened: According to U.S. Securities and Exchange Commission filings from February 14, Miller Value Partners, which investor Bill Miller III&#8216;s son runs, added three stocks to its portfolio in the fourth quarter of 2024. Since then, these stocks have seen significant drops.
All three new positions have faltered:
Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) fell 25.07%, losing $908,600 in value on its 70,000-share position. Carlyle CEO Harvey Schwartz recently <a href="https://www.semafor.com/article/04/24/2025/carlyle-group-ceo-harvey-schwartz-investors-want-to-know-trumps-rule-set">cited</a> policy uncertainty as a major market challenge during Semafor&#8217;s World Economy Summit, noting that businesses &#8220;need a rule set so they can optimize.&#8221;
Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) dropped 11.04%, representing a $296,370 loss on 37,000 shares. The electrical products manufacturer recently announced a $121-162 million impairment charge related to HDPE assets while maintaining its full-year fiscal 2025 outlook. The company also faces a securities lawsuit alleging it engaged in price-fixing schemes for PVC pipes.
Semler Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) suffered the steepest decline at 30.66%, with 43,000 shares losing $651,990 in value. Since December, Semler&#8217;s stock has plummeted over 52%, prompting an investigation by Kaskela Law on behalf of long-term investors.
The losses in Miller Value Partners' fourth-quarter portfolio additions appear to align with broader market trends.
The Dimensional ETF Trust Dimensional U.S. Core Equity 2 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFAC#NYSE">DFAC</a>), which holds Carlyle Group stock, has dropped 10.62%, from $66.80 to $59.70. The First Trust RBA American Industrial Renaissance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRR#NASDAQ">AIRR</a>), which includes Atkore, has fallen 9.28%, from $77.20 to $70.03. Meanwhile, Schwab Strategic Trust Schwab Crypto Thematic ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STCE#NYSE">STCE</a>), which includes Semler Scientific Inc., has experienced a 26.31% decline, from $49.59 to $36.54.
See Also:&nbsp;<a href="https://www.benzinga.com/personal-finance/25/04/44940178/warren-buffett-says-millions-are-trapped-living-an-american-nightmare-but-proposes-a-tool-far-more-useful-than-raising-minimum-wage" target="_blank" rel="noreferrer noopener">Warren Buffett Says Millions Are Trapped Living An ‘American Nightmare' — But Proposes A Tool ‘Far More Useful' Than Raising Minimum Wage</a>
<a href="https://www.benzinga.com/go/ibkr-widget" target="_blank" rel="noreferrer noopener"></a><a href="https://www.benzinga.com/go/ibkr-widget" target="_blank" rel="noreferrer noopener"></a>Why It Matters: Despite these setbacks, analysts see potential upside. Recent ratings suggest implied gains of 2.56% for Carlyle Group, 3.88% for Atkore, and a substantial 70.34% for Semler Scientific from current levels, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
The family investment philosophy follows Bill Miller III&#8217;s legacy of <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44640955/bill-millers-firm-slashed-microstrategy-stake-by-70-the-move-that-dodged-a-costly-hit">contrarian value investing</a>. The senior Miller, famous for beating the S&amp;P 500 for 15 consecutive years at Legg Mason Value Trust, remains a vocal Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) advocate, calling it &#8220;an insurance policy against financial catastrophe.&#8221;
Miller Value Partners currently manages <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44640955/bill-millers-firm-slashed-microstrategy-stake-by-70-the-move-that-dodged-a-costly-hit">approximately $290 million in assets</a> through its Miller Income mutual fund and two ETFs.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44969001/65-year-old-with-110k-saved-asks-if-he-can-retire-in-7-years-dave-ramsey-says-you-have-no-money-and-tells-him-to-stop-401k-contributions" target="_blank" rel="noreferrer noopener">65-Year-Old With $110K Saved Asks If He Can Retire in 7 Years — Dave Ramsey Says ‘You Have No Money' and Tells Him to Stop 401(k) Contributions</a></li>
</ul>
Photo Courtesy: JOURNEY STUDIO7 On Shutterstock.com
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

AIRR

ATKR

DFAC

STCE

Bill Miller's Q4 Additions Struggle Amid Market Uncertainty, What Else Is Dragging Them Down?

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="582" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23030113/Rollercoaster-1024x582.jpg" alt="" class="wp-image-11367" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23030113/Rollercoaster-1024x582.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23030113/Rollercoaster-300x171.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23030113/Rollercoaster-768x436.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23030113/Rollercoaster.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Here We Go Again&nbsp;</h2>
Warren Buffett&#8217;s mentor Benjamin Graham famously described the stock market as a mentally ill man (&#8220;Mr. Market&#8221;) who toggled between euphoria and despair. There&#8217;s an additional twist today, with Wall Street leaning left. Investment professionals on our X&nbsp;<a href="https://x.com/i/lists/1612691584155324417">Market Watchers list</a>&nbsp;alternate between rage against Trump and contempt for him.&nbsp;
We saw that today, as markets&nbsp;<a href="https://www.zerohedge.com/market-recaps/bitcoin-bid-gold-skids-stocks-bounce-amid-soft-data-slump">ripped higher</a>&nbsp;after hours on President Trump&#8217;s comments. ZeroHedge led with the news that Trump said he wouldn&#8217;t fire Fed Chairman Powell. But on our Market Watchers list, the focus was on tariffs. On Monday, they railed against Trump for wrecking the economy (as they saw it) with tariffs; on Tuesday, they mocked him for signaling some flexibility on them.&nbsp;
<h2 class="wp-block-heading">Tuesday&#8217;s Contempt For Trump</h2>
Here&#8217;s a small sample from our Market Watchers list: 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">And this is what it's like watching your opponent commit suicide <a href="https://t.co/TKcxZdO2FX">https://t.co/TKcxZdO2FX</a>
&mdash; Eliant Capital (@eliant_capital) <a href="https://twitter.com/eliant_capital/status/1914794195878879707?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f979; <a href="https://t.co/pmK5VzAAdm">pic.twitter.com/pmK5VzAAdm</a>
&mdash; Le Shrub&#x1f333;&#x1f525;&#x1f1fa;&#x1f1e6; (@agnostoxxx) <a href="https://twitter.com/agnostoxxx/status/1914799482513809503?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f602;&#x1f602;&#x1f602;&#x1f602;&#x1f602; <a href="https://t.co/PMInU7PZG8">pic.twitter.com/PMInU7PZG8</a>
&mdash; PiQ (@PiQSuite) <a href="https://twitter.com/PiQSuite/status/1914801599287058900?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">They looked you in the face and said it was Main Street's turn Then the The Treasury Secretary held a closed door meeting with Wall Street and said he "expected the situation to de-escalate" a day before Trump capitulated…for nothing in return
&mdash; BuccoCapital Bloke (@buccocapital) <a href="https://twitter.com/buccocapital/status/1914813577757667706?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;Trump capitulated&#8221; because he said the final tariffs on China are going to be&nbsp;somewhere below 145%? We&#8217;ll see.
<h2 class="wp-block-heading">Maybe Trump&#8217;s Critics Are Right</h2>
Let&#8217;s concede the possibility that Trump is going to completely fold on tariffs. On the one hand, America&#8217;s trade deficits have been one of Trump&#8217;s two biggest political concerns since <a href="https://www.playboy.com/read/playboy-interview/playboy-interview-donald-trump-1990/">at least 1990</a> (his other concern: avoiding nuclear war). 
<figure class="wp-block-image aligncenter size-large"><a href="https://www.playboy.com/read/playboy-interview/playboy-interview-donald-trump-1990/"><img loading="lazy" decoding="async" width="1024" height="550" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23032303/Trump-Playboy-1-1024x550.jpg" alt="" class="wp-image-11368" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23032303/Trump-Playboy-1-1024x550.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23032303/Trump-Playboy-1-300x161.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23032303/Trump-Playboy-1-768x412.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23032303/Trump-Playboy-1.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Also, Trump&#8217;s strongest support today comes from groups that don&#8217;t own a lot of stock, like young men (and very young women). 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Women R+4 among 18-21&#39;s is "the nightmare is just beginning"-tier for the left. <a href="https://t.co/TLzw3RhuRK">https://t.co/TLzw3RhuRK</a>
&mdash; Just Loki (@LokiJulianus) <a href="https://twitter.com/LokiJulianus/status/1914422701743382817?ref_src=twsrc%5Etfw">April 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
And, as we saw above, some Wall Streeters have contempt for him.&nbsp;
On the other hand&#8230;what? Trump is going to fold on his goal of reindustrializing America to please them? It&#8217;s possible, but we wouldn&#8217;t bet on that. Here&#8217;s what we have been betting on.&nbsp;
<h2 class="wp-block-heading">How We&#8217;re Playing The Market Roller Coaster&nbsp;</h2>
Our gameplan has basically been to buy the dips and fade the rallies. That&#8217;s what we&#8217;ve done so far this week.&nbsp;
On Monday, when the market tanked, we took profits on a couple of our bearish big tech bets:
Options
<ol>
<li>Puts on Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). Bought for $1.81 on <a href="https://portfolioarmor.substack.com/p/trade-alert-betting-against-the-bounce">4//14/2025</a>; sold for $2.71 on <a href="https://portfolioarmor.substack.com/p/trade-alert-betting-against-the-bounce/comment/110875000">4/21/2025</a>. Profit: 50%.</li>
<li>Puts on Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). Bought for $1.56 on <a href="https://portfolioarmor.substack.com/p/trade-alert-monster-rally">4/9/2025</a>; sold for $4.02 on <a href="https://portfolioarmor.substack.com/p/trade-alert-monster-rally/comment/110877872">4/21/2025</a>. Profit: 158%.</li>
</ol>
And added <a href="https://portfolioarmor.substack.com/p/trade-alert-bitcoin-bull">a couple of bullish bets</a> on Bitcoin-related names. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24AAPL&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$AAPL</a> <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a><a href="https://t.co/vJNbgejQ79">https://t.co/vJNbgejQ79</a>
&mdash; Portfolio Armor (@PortfolioArmor) <a href="https://twitter.com/PortfolioArmor/status/1914374100694315123?ref_src=twsrc%5Etfw">April 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
One of those bullish bets was on Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), a profitable medical tech company that borrowed Michael Saylor&#8217;s Bitcoin Balance Sheet strategy. SMLR closed up 11.57% on Tuesday. 
On Tuesday, when the market rallied, we <a href="https://portfolioarmor.substack.com/p/trade-alert-tariff-fallout">added bearish bets</a> against two of the main vendors used by American small businesses that import from China. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SPY&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPY</a><a href="https://t.co/7fiDKQNDFW">https://t.co/7fiDKQNDFW</a>
&mdash; Portfolio Armor (@PortfolioArmor) <a href="https://twitter.com/PortfolioArmor/status/1914712758643261451?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
If the market rallies again on Wednesday, we&#8217;ll be adding more short exposure. If you want a heads up when we do, you can subscribe to our trading Substack/occasional email list below.&nbsp;
And if you want to take advantage of the rally to hedge, 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SPY&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPY</a> <a href="https://twitter.com/search?q=%24QQQ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$QQQ</a> <a href="https://t.co/CE1xSWLwcH">https://t.co/CE1xSWLwcH</a>
&mdash; Portfolio Armor (@PortfolioArmor) <a href="https://twitter.com/PortfolioArmor/status/1914733519273594937?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
As a reminder, you can download the Portfolio Armor optimal hedging app by aiming your iPhone camera at the QR code below (or by <a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone). Our app can help you find the least expensive hedges given your risk tolerance and time frame.
<figure class="wp-block-image size-full"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23033219/QR-Code-6.jpg" alt="" class="wp-image-11369" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and create hedged portfolios on <a href="https://portfolioarmor.com/">our website</a>. You can also follow Portfolio Armor on X <a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23033408/Widget-5.jpg" alt="" class="wp-image-11370" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23033408/Widget-5.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23033408/Widget-5-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Options

Opinion

AAPL

NVDA

Bipolar Market Rips Higher On False Hope

Healthcare technology company Semler Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) announced its latest securities offering Tuesday to add to its fast-expanding Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) stockpile.
What happened: In a Form S-3 registration statement with the SEC, the firm proposed to offer $500 million in securities, including debt securities, common stock, units, and warrants.
"We intend to use the net proceeds from the sale of any securities offered under this prospectus primarily for general corporate purposes, including the acquisition of Bitcoin," Semler said.&nbsp;
Semler <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/3904">adopted Bitcoin as its primary treasury reserve asset</a> in May 2024,&nbsp; funding its purchases through corporate maneuvers such as equity and debt financings, as well as cash flows from its operations.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/04/44831018/cathie-wood-declares-financial-services-revolution-after-data-shows-decentralized-finance-surpassing-traditional-banking-system">Cathie Wood Calls It &#8216;Financial Services Revolution&#8217; After Ark Analyst Highlights DeFi&#8217;s Dominance Over Traditional Banking System</a>
Earlier in January, the firm<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43195291/microstrategy-devotee-semler-scientific-doubles-down-on-bitcoin-buys"> issued convertible bonds worth $85 million</a> and used proceeds from the transaction to add to its Bitcoin reserves.
Metaplanet owned 3,192 BTCs worth $280 million as of this writing, making it the 12th-largest corporate holder of the leading cryptocurrency, <a href="https://bitcointreasuries.net/">according </a>to BitcoinTreasuries data.&nbsp;
Interestingly, the decision to buy more comes despite the firm&#8217;s 5% unrealized loss on Bitcoin assets.
Why It Matters: Semler's fundraising efforts come amid a broader trend of corporate Bitcoin adoption, evangelized by Michael Saylor's Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), <a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43878748/michael-saylor-bitcoin-is-economic-armor-calls-on-us-to-accumulate-btc">the world's biggest BTC hoarder</a>.
Japan-based Metaplanet Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MTPLF#OTC">MTPLF</a>), currently the tenth-largest corporate Bitcoin holder, has <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44807580/eric-trump-celebrates-metaplanets-bitcoin-moonshot-as-japanese-firm-rockets-into-top-10-corporate-holders-with-388-million-btc-stash">followed the same playbook</a>.
In other news, Semler reached a $29.75 million settlement with the Justice Department, resolving claims of violations of a <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/39042812/semler-scientific-28-after-adopting-bitcoin-as-primary-treasury-reserve-asset-whats-going-">federal anti-fraud law</a> related to its marketing of a product known as QuantaFlo.
Price Action: At the time of writing, Bitcoin traded at $83,169.20, down 3.11% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;
Semler shares were down 0.15% in after-hours trading after closing 0.41% higher at $34.40 during Tuesday&#8217;s regular session. 
The stock demonstrated high momentum—the measure of a stock&#8217;s relative strength based on its price movement patterns and volatility over multiple timeframes—as of this writing. Visit <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge Stock Rankings </a>to compare how other Bitcoin-buying companies like Strategy score on this metric.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44832008/peter-schiff-says-since-trump-was-elected-bitcoin-advocates-took-a-180-turn-on-us-economy-but-critics-say-economist-mistaken">Peter Schiff Says Since Trump Was Elected Bitcoin Advocates Took A 180 Turn On US Economy, But Critics Say Economist Mistaken</a></li>
</ul>
Image Via Shutterstock

Despite Unrealized Losses, Semler Scientific Plans $500 Million Securities Offering To Boost Bitcoin Holdings

Although it has not yet finalized its full financial results for the first quarter ended March&nbsp;31, 2025, Semler Scientific,&nbsp;Inc., or Semler Sci, is providing select preliminary unaudited financial information for the first quarter ended March&nbsp;31, 2025 and an update on its Bitcoin holdings as of March&nbsp;31, 2025.
&nbsp;
Semler Sci anticipates reporting for the first three months ended and as of March&nbsp;31, 2025:
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Revenues of $8.8 to $8.9 million.</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Loss from operations of $1.3 to $1.5 million (which includes approximately $1.5 million of non-cash stock compensation, $0.4 million in state sales and use tax accrual, and $0.4 million in legal fees relating to the U.S. Department of Justice, or DOJ, civil investigative demand, or CID).</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Unrealized loss from the change in fair value of bitcoin holdings since December&nbsp;31, 2024 of approximately $41.8 million.</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Bitcoin holdings of 3,192 bitcoins as of March&nbsp;31, 2025, valued at approximately $263.5 million.</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Contingent liability relating to the settlement of DOJ CID of approximately $29.75 million.</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Cash, restricted cash and cash equivalents as of March&nbsp;31, 2025 of approximately $9.9 million.</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Semler Scientific Expects Q1 Revenues Of $8.8M-$8.9M; Holds 3,192 Bitcoins Valued At ~$263.5M

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is increasingly popular <a href="https://www.benzinga.com/25/03/44569292/congressman-buys-up-to-600k-in-bitcoin-etf-after-selling-1-million-in-goldman-sachs-stock-committee-assignment-could-be-red-flag">among corporate buyers</a>, with on-chain data suggesting ongoing accumulation by other large entities.
What Happened: In a detailed X <a href="https://x.com/cryptoquant_com/status/1907377531143016915">thread</a> on Wedneday, research firm CryptoQuant pointed out that despite public companies accumulating 91,781 BTC in Q1, Bitcoin dropped 12%, from $94,400 to $82,500. 
Tether emerged as a surprise buyer, adding 8,888 BTC, while Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) made the largest move, acquiring 81,785 BTC for more than $8 billion.
Other buyers included The Blockchain Company (+605 BTC), Semler Scientific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) (+1,108 BTC) and Metaplanet (+2,285 BTC) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MTPLF#OTC">MTPLF</a>). 
On-chain analytics shows more corporate buying could be on the horizon, with Marathon Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) planning a $2 billion stock sale for BTC purchases and GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) exploring a $1.3 billion Bitcoin strategy through a convertible note offering.
However, the price decline was driven by long-term holders selling 178,000 BTC in Q1, outweighing corporate accumulation. Additionally, $4.8 billion in Bitcoin ETF outflows added further downward pressure on price.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44581901/bitcoin-is-in-a-mini-bear-market-says-10x-research">Bitcoin Is In A Mini Bear Market, Says 10x Research</a>
Why It Matters: Glassnode data listed several bullish indicators for Bitcoin:
<ul>
<li>Retail investors (under 1 BTC) are <a href="https://x.com/glassnode/status/1907358419859669116">offloading</a> while whales (10+ BTC) accumulate, highlighting a divergence in investor sentiment.</li>
<li>Bitcoin holders in the 3–6-month range (nearing long-term holder status) are <a href="https://x.com/glassnode/status/1906713577471234255">holding</a> strong despite volatility. Spending activity from this group is at its lowest since mid-2021, suggesting conviction, not panic selling.</li>
<li>BTC holders from 2020-2022 are still <a href="https://x.com/glassnode/status/1907001005251625160">holding</a> significant wealth, despite a 3% decline in their share since the November 2024 peak.</li>
</ul>
Crypto investor and entrepreneur Ted Pillows <a href="https://x.com/TedPillows/status/1907347270028116195">highlighted</a> Bitcoin ETF outflows of $157.8 million on Tuesday amid concerns over Trump&#8217;s tariff policy.
What's Next: Crypto trader Altcoin Sherpa notes sideways price action, with a lower low on the 4-hour chart.
The traders urges caution, with volatility expected in the current week.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Arguments all over the place on what <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> price is doing, this entire consolidation region is just a chop fest. Can make arguments that we just made a lower low on the 4h but I don&#39;t think you can really tell too much on this price action. Would rather just be on guard over the… <a href="https://t.co/B2ZSk1CtZu">pic.twitter.com/B2ZSk1CtZu</a>
&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1907398858654482891?ref_src=twsrc%5Etfw">April 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44583918/bitcoin-reclaims-84000-is-the-correction-nearing-its-end">Bitcoin Reclaims $84,000: Is The Correction Nearing Its End?</a></li>
</ul>
Image: Shutterstock

Bitcoin Slips 12% In 3 Months Despite Corporate Buying – What's Behind The Decline And What's Next?

Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) reported quarterly earnings of $3.41 per share which beat the analyst consensus estimate of $0.20 by 1605 percent. This is a 520 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $12.41 million which beat the analyst consensus estimate of $12.00 million by 3.44 percent. This is a 17.55 percent decrease over sales of $15.06 million the same period last year.

Earnings Beats

Semler Scientific Q4 EPS $3.41 Beats $0.20 Estimate, Sales $12.41M Beat $12.00M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Sohu.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHU#NASDAQ">SOHU</a>) is estimated to report earnings for its fourth quarter. 
• Expeditors Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>) is projected to report quarterly earnings at $1.44 per share on revenue of $2.81 billion. 
• Franklin Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FELE#NASDAQ">FELE</a>) is expected to report quarterly earnings at $0.66 per share on revenue of $465.87 million. 
• Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) is estimated to report quarterly earnings at $3.62 per share on revenue of $1.01 billion. 
• GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $82.24 million. 
• Watsco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) is projected to report quarterly earnings at $2.19 per share on revenue of $1.67 billion. 
• Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $350.45 million. 
• Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) is estimated to report quarterly earnings at $1.75 per share on revenue of $1.81 billion. 
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $173.40 million. 
• Donnelley Financial Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFIN#NYSE">DFIN</a>) is estimated to report quarterly earnings at $0.49 per share on revenue of $169.20 million. 
• Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) is projected to report quarterly loss at $0.99 per share on revenue of $117.83 million. 
• Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $5.71 billion. 
• Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) is likely to report quarterly earnings at $1.97 per share on revenue of $954.17 million. 
• Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $1.37 billion. 
• Sapiens Intl Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $135.89 million. 
• Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) is likely to report quarterly earnings at $0.77 per share on revenue of $4.42 billion. 
• Allegion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>) is expected to report quarterly earnings at $1.75 per share on revenue of $938.91 million. 
• iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $909.96 million. 
• Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) is projected to report quarterly earnings at $0.64 per share on revenue of $3.17 billion. 
• Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) is expected to report quarterly earnings at $1.78 per share on revenue of $4.56 billion. 
• Great Lakes Dredge &amp; Dock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $211.20 million. 
• Blackbaud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLKB#NASDAQ">BLKB</a>) is likely to report quarterly earnings at $1.07 per share on revenue of $303.41 million. 
• Waystar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $232.29 million. 
• Tri Pointe Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPH#NYSE">TPH</a>) is expected to report quarterly earnings at $1.29 per share on revenue of $1.22 billion. 
• Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $8.33 billion. 
<h3>Companies Reporting After The Bell</h3>
• James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $960.80 million. 
• RB Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) is projected to report quarterly earnings at $0.79 per share on revenue of $1.06 billion. 
• Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) is expected to report earnings for its first quarter. 
• Safe Bulkers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $71.90 million. 
• ReNew Energy Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNW#NASDAQ">RNW</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $264.79 million. 
• Select Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTTR#NYSE">WTTR</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $338.92 million. 
• Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) is expected to report quarterly earnings at $0.28 per share on revenue of $85.39 million. 
• TPG RE Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRTX#NYSE">TRTX</a>) is projected to report quarterly earnings at $0.26 per share on revenue of $27.98 million. 
• SiriusPoint (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPNT#NYSE">SPNT</a>) is likely to report earnings for its fourth quarter. 
• Star Bulk Carriers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBLK#NASDAQ">SBLK</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $238.48 million. 
• TrueCar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) is expected to report quarterly loss at $0.02 per share on revenue of $47.30 million. 
• BlueLinx Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXC#NYSE">BXC</a>) is likely to report quarterly earnings at $0.52 per share on revenue of $700.66 million. 
• Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) is projected to report quarterly loss at $0.03 per share on revenue of $1.29 billion. 
• Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) is projected to report quarterly loss at $0.16 per share on revenue of $114.25 million. 
• Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) is projected to report quarterly loss at $0.05 per share on revenue of $3.14 billion. 
• Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) is expected to report quarterly loss at $0.24 per share on revenue of $781.68 million. 
• Perdoceo Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $160.12 million. 
• Iamgold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) is likely to report earnings for its fourth quarter. 
• La-Z-Boy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZB#NYSE">LZB</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $516.47 million. 
• CVR Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAN#NYSE">UAN</a>) is likely to report earnings for its fourth quarter. 
• CVR Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $1.93 billion. 
• Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) is likely to report quarterly earnings at $1.17 per share on revenue of $286.07 million. 
• Sonoco Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>) is likely to report quarterly earnings at $1.22 per share on revenue of $1.65 billion. 
• CoStar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $701.59 million. 
• Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) is expected to report quarterly earnings at $0.78 per share on revenue of $123.21 million. 
• Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFA#NASDAQ">BELFA</a>) is estimated to report quarterly earnings at $1.01 per share on revenue of $128.50 million. 
• Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $15.18 million. 
• Unisys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $550.93 million. 
• Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) is expected to report quarterly earnings at $2.05 per share on revenue of $1.91 billion. 
• XP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $828.34 million. 
• Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $600.32 million. 
• Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $726.70 million. 
• Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) is estimated to report quarterly earnings at $0.31 per share on revenue of $260.00 million. 
• Center (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSR#NYSE">CSR</a>) is estimated to report quarterly earnings at $1.19 per share on revenue of $65.70 million. 
• Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $1.21 billion. 
• Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $12.00 million. 
• Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $2.69 billion. 
• SSR Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSRM#NASDAQ">SSRM</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $244.25 million. 
• BrightSpire Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRSP#NYSE">BRSP</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $48.20 million. 
• Corporacion Inmobiliaria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTMX#NYSE">VTMX</a>) is likely to report earnings for its fourth quarter. 
• Hackett Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $75.64 million. 
• Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) is projected to report quarterly earnings at $0.57 per share on revenue of $1.90 billion. 
• Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) is expected to report quarterly earnings at $0.90 per share on revenue of $311.52 million. 
• JBG SMITH Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBGS#NYSE">JBGS</a>) is projected to report earnings for its fourth quarter. 
• Seven Hills Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEVN#NASDAQ">SEVN</a>) is estimated to report quarterly earnings at $0.34 per share on revenue of $8.31 million. 
• Industrial Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILPT#NASDAQ">ILPT</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $110.30 million. 
• Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) is estimated to report quarterly earnings at $1.84 per share on revenue of $999.09 million. 
• Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) is projected to report quarterly earnings at $0.74 per share on revenue of $7.04 billion. 
• Community Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHCT#NYSE">CHCT</a>) is expected to report quarterly earnings at $0.54 per share on revenue of $29.90 million. 
• Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) is estimated to report quarterly earnings at $0.42 per share on revenue of $113.93 million. 
• Rush Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUSHB#NASDAQ">RUSHB</a>) is expected to report earnings for its fourth quarter. 
• Rush Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUSHA#NASDAQ">RUSHA</a>) is projected to report quarterly earnings at $0.83 per share on revenue of $1.86 billion. 
• Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) is expected to report quarterly earnings at $1.20 per share on revenue of $997.44 million. 
• Ingevity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $315.20 million. 
• Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) is estimated to report quarterly earnings at $1.25 per share on revenue of $2.39 billion. 
• MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $722.85 million. 
• Gladstone Commercial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOD#NASDAQ">GOOD</a>) is estimated to report quarterly earnings at $0.36 per share on revenue of $38.20 million. 
• EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $1.82 billion. 
• Comstock Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRK#NYSE">CRK</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $378.74 million. 
• Genworth Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNW#NYSE">GNW</a>) is likely to report earnings for its fourth quarter. 
• Innospec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOSP#NASDAQ">IOSP</a>) is estimated to report quarterly earnings at $1.37 per share on revenue of $447.40 million. 
• Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $330.88 million. 
• Sasol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) is expected to report earnings for its fourth quarter. 
• Sandstorm Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) is expected to report earnings for its fourth quarter. 
• Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) is expected to report quarterly earnings at $1.31 per share on revenue of $4.30 billion. 
• Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is estimated to report quarterly earnings at $1.83 per share on revenue of $1.35 billion. 
• Ternium (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TX#NYSE">TX</a>) is projected to report quarterly earnings at $1.28 per share on revenue of $4.49 billion. 
• Andersons (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANDE#NASDAQ">ANDE</a>) is likely to report quarterly earnings at $0.94 per share on revenue of $2.73 billion. 
• Liberty Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYA#NASDAQ">LBTYA</a>) is likely to report quarterly loss at $0.96 per share on revenue of $1.95 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Semler Scientific

Noticias

Últimas noticias sobre Semler Scientific (NASDAQ:SMLR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL